Promising cancer drug trial halted after just one patient
NCT ID NCT05987176
First seen Jan 17, 2026 · Last updated Jun 21, 2026 · Updated 24 times
Summary
This study aimed to see if giving Lutathera (a radioactive drug) after surgery to remove liver metastases from neuroendocrine tumors could help keep the cancer from coming back. It planned to compare Lutathera plus best supportive care against best supportive care alone in about 100 patients. However, the trial was terminated early after enrolling only 1 person, so no useful results were obtained.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust
London, W12 0HS, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutathera (177Lu-DOTATATE)
What this could lead to
If it had worked, this could have pointed toward a way to delay or prevent cancer return after liver surgery for neuroendocrine tumors.
What could go wrong
The trial was terminated early with only 1 participant, so no conclusions can be drawn. Lutathera also carries risks like kidney and bone marrow damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.